Sugar Substitute Xylitol Tied to Higher Risk of Heart Attack, Stroke, and Death, Study Finds

A new study has identified a potential link between the artificial sweetener xylitol and an increased risk of major cardiovascular events. According to reports from Gizmodo, Newsweek, and Medical News Today, the research indicates that the use of this sugar substitute is tied to a 57% higher risk of suffering a heart attack or stroke. The findings suggest that xylitol, which is widely used in a variety of consumer products, may be associated with a higher risk of death and adverse cardiovascular outcomes. This discovery has prompted health warnings across multiple media outlets regarding the safety of the sweetener for heart health. Coverage of these findings is extensive, with reports appearing in diverse outlets including the New York Post, The Independent, and U.S. Many of these publications, such as The Sun and SheKnows, emphasize that xylitol is a common ingredient found in everyday items like chewing gum, soda, and jam.

Furthermore, Pharmaceutical Technology highlights that xylitol is used as a common pharmaceutical excipient. While the majority of reports focus on the risk increase, PolitiFact has noted that some of the news surrounding these links to heart health lacks important details, suggesting a need for caution before causing undue stress to consumers. To understand why this is trending, it is necessary to recognize the prevalence of xylitol in the modern diet. As noted by Newsweek, millions of people utilize this sugar substitute as an alternative to sucrose. Because it is integrated into such a wide array of products—ranging from confectionery and beverages to medicinal formulations—any link to major cardiovascular events represents a potential public health concern. The study's results have led outlets like Healthline and Everyday Health to provide platforms for doctors to explain the new findings to a public that frequently consumes these sweeteners in their daily routines.

Moving forward, the focus will remain on the data presented at ESC 2026, as mentioned by Dermatology Advisor and Pharmaceutical Technology. Observers will be watching for further details regarding the specifics of the study that PolitiFact indicated were missing from early reports. Future coverage is expected to clarify the exact nature of the cardiovascular risk and whether regulatory bodies will issue new guidelines for the use of xylitol in food and pharmaceutical products. The ongoing dialogue between medical experts and the public will likely center on whether the 57% risk increase necessitates a change in dietary habits for millions of users.